| NCT06143956A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | Eloralintide, Macupatide, Mazdutide, Tirzepatide Obesity / overweight | — | Ph 2 | Recruiting | 53 | Sep 2027 | — | |
| NCT06124807A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight | Mazdutide Obesity / overweight | BMI ≥27 | Ph 2 | Completed | 29 | Jan 2025 | — | results |
| NCT06817356A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder | Mazdutide Alcohol / substance use | — | Ph 2 | Active, not recruiting | 25 | Aug 2026 | — | |
| NCT05607680A Study of IBI362 in Participants With Obesity or Overweight | Mazdutide Obesity / overweight | BMI ≥28 | Ph 3 | Completed | 23 | Aug 2023 | 1 | |
| SMARTMazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity | Mazdutide Bariatric Surgery, Obesity / overweight | BMI ≥37.5 | Not applicable | Not yet recruiting | 14 | Sep 2027 | — | |
| NCT07517042ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management | Mazdutide Obesity / overweight | BMI 28-45 | Not applicable | Recruiting | 13 | Dec 2028 | — | |
| NCT07083154GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study) | Mazdutide Alzheimer's / cognition, Type 2 diabetes | BMI ≥20 | Ph 3 | Recruiting | 8 | Aug 2029 | — | |
| NCT05623839A Study of LY3305677 in Participants With Obesity Or Overweight | Mazdutide Obesity / overweight | BMI 27-50 | Ph 1 | Completed | 3 | Jun 2023 | 1 | |
| NCT07255209A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | Mazdutide Obesity / overweight | BMI 586-2018 | Ph 3 | Recruiting | 1 | Oct 2027 | — | |
| NCT06884293A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD） | Mazdutide, Semaglutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥27 | Ph 3 | Active, not recruiting | 1 | Dec 2026 | — | |
| NCT04773977Clinical Study of IBI362 in Healthy Chinese Male Subjects | Mazdutide Healthy volunteers | BMI ≤26 | Ph 1 | Completed | 1 | Mar 2021 | — | |
| NCT06862908A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Mazdutide Heart failure, Obesity / overweight | BMI ≥28 | Ph 2 | Recruiting | 1 | Sep 2026 | — | |
| NCT06937749A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Mazdutide MASH / NAFLD / liver fibrosis, Obesity / overweight | BMI ≥25 | Ph 2 | Recruiting | 1 | Apr 2026 | — | |
| NCT07657676Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity | Mazdutide Cardiovascular disease, Obesity / overweight | BMI ≥28 | Ph 4 | Not yet recruiting | 1 | Oct 2027 | — | |
| NCT04965506A Study of IBI362 in Chinese Patients With Type 2 Diabetes | Dulaglutide, Mazdutide Type 2 diabetes | HbA1c 7-10.5% | Ph 2 | Completed | 1 | Apr 2022 | 1 | |
| NCT05815680A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects | Mazdutide Obesity / overweight | BMI 24-30 | Ph 1 | Completed | 1 | Aug 2023 | — | |
| NCT03928379A Study of LY3305677 in Participants With Type 2 Diabetes | Mazdutide Obesity / overweight, Type 2 diabetes | BMI 25-40 | Ph 1 | Completed | 1 | Jul 2021 | — | |
| NCT04466904Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM | Dulaglutide, Mazdutide Type 2 diabetes | BMI ≤35 | Ph 1/2 | Completed | 1 | May 2021 | 1 | |
| NCT06931028A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | Mazdutide Obesity / overweight, Sleep apnea | BMI ≥28 | Ph 3 | Recruiting | 1 | May 2027 | — | |
| NCT07000955Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Mazdutide, Tirzepatide Obesity / overweight | BMI ≥32.5 | Ph 1/2 | Active, not recruiting | 1 | Sep 2026 | — | |
| NCT05628311A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise | Mazdutide Type 2 diabetes | HbA1c ≤10.5% | Ph 3 | Completed | 1 | Oct 2023 | — | |
| NCT07469800Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity | Mazdutide Hypertension, Obesity / overweight | — | Ph 3 | Recruiting | 1 | Aug 2026 | — | |
| DREAM-PREMazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) | Mazdutide Prediabetes / glucose intolerance | BMI ≥22 | Ph 4 | Not yet recruiting | 1 | Jun 2028 | 9 | |
| NCT03325387A Study of Multiple Doses of LY3305677 in Healthy Participants | Mazdutide Healthy volunteers | Healthy volunteers | Ph 1 | Completed | 1 | Aug 2018 | — | |
| NCT06536023This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity | Mazdutide Obesity / overweight | BMI 586-2018 | Ph 1 | Completed | 1 | Jul 2025 | — | |
| NCT06184568A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity | Mazdutide, Semaglutide Obesity / overweight, Type 2 diabetes | BMI ≥28 | Ph 3 | Active, not recruiting | 1 | Sep 2025 | — | |
| NCT07417306A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor | HDM1005, Mazdutide Type 2 diabetes | BMI ≥22.5 | Ph 3 | Not yet recruiting | 1 | Aug 2027 | — | |
| NCT05606913A Study of IBI362 in Participants With Type 2 Diabetes | Dulaglutide, Mazdutide Obesity / overweight, Type 2 diabetes | BMI ≥23 | Ph 3 | Completed | 1 | Jan 2024 | 1 | |
| NCT02972645A Study of LY3305677 in Healthy Participants | Mazdutide Healthy volunteers | Healthy volunteers | Ph 1 | Completed | 1 | Jul 2017 | — | |
| NCT06164873A Study of IBI362 9 mg in Chinese Adults With Obesity | Mazdutide Obesity / overweight | BMI ≥30 | Ph 3 | Active, not recruiting | 1 | Jun 2025 | — | |
| NCT06519656Efficacy of Mazdutide for Treating PCOS | Mazdutide Obesity / overweight, PCOS | BMI ≥28 | Ph 1/2 | Recruiting | 1 | Dec 2025 | — | |
| NCT04904913A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects | Mazdutide Obesity / overweight | BMI ≥28 | Ph 2 | Completed | 1 | Mar 2023 | 1 | |
| NCT07633639GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Mazdutide, Semaglutide, Tirzepatide Bariatric Surgery, Obesity / overweight | BMI ≥30 | Not applicable | Recruiting | 1 | May 2028 | — | |
| NCT05793450Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment | Mazdutide Healthy volunteers, Renal impairment | eGFR ≥90 | Ph 1 | Completed | 1 | Sep 2023 | — | |
| NCT04440345Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects | Mazdutide Obesity / overweight | BMI ≥24 | Ph 1/2 | Completed | 1 | Jun 2021 | 2 | |
